Stem Cells to Treat Lung Disease in Preterm Infants
Cincinnati, OH, February 6, 2014
Advances in neonatal care for very preterm infants have
greatly increased the chances of survival for these fragile infants. However, preterm infants have an increased
risk of developing bronchopulmonary dysplasia (BPD), a serious lung disease,
which is a major cause of death and lifelong complications. In a new study scheduled for publication in
The Journal of Pediatrics, researchers evaluated the safety and feasibility of
using stem cell therapies on very preterm infants to prevent or treat BPD.
Won Soon Park, MD, PhD, and colleagues from Samsung Medical Center and Biomedical Research Institute, Seoul, Republic of Korea, conducted a phase I, single-center trial of intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells to nine very preterm infants (24-26 weeks gestational age) who were at high risk of developing BPD.
All patients who received the treatment tolerated the procedure well without any immediate serious adverse effects. Thirty-three percent of treated infants developed moderate BPD and none developed severe BPD, and 72 percent of a matched comparison group developed moderate or severe BPD. Another serious side effect of very preterm birth, retinopathy of prematurity requiring surgery, tended to occur less often in treated infants. Overall, all nine treated infants survived to discharge, and only three developed moderate BPD.
This phase I study suggests that intratracheal administration of mesenchymal stem cells is safe and feasible. According to Dr. Park, "These findings strongly suggest that phase II clinical trials are warranted to test the efficacy of mesencymal stem cell transplantation, which could lead to new therapies to prevent or cure BPD." Dr. Park and colleagues are currently conducting a long-term safety and follow-up study of these nine preterm infants (ClinicalTrials.gov: NCT01632475).
# # #
Notes for editors
"Mesenchymal Stem Cells for Bronchopulmonary Dysplasia: Phase 1 Dose-Escalation Clinical Trial," by Yun Sil Chang, MD, PhD, So Yoon Ahn, MD, Hye Soo Yoo, MD, Se In Sung, MD, Soo Jin Choi, MD, PhD, Won Il Oh, MD, PhD, Woon Soon Park, MD, appears in The Journal of Pediatrics (www.jpeds.com), DOI 10.1016/j.jpeds.2013.12.011, published by Elsevier.
About The Journal of Pediatrics
The Journal of Pediatrics is a primary reference for the science and practice of pediatrics and its subspecialties. This authoritative resource of original, peer-reviewed articles oriented toward clinical practice helps physicians stay abreast of the latest and ever-changing developments in pediatric medicine. The Journal of Pediatrics is ranked 4th out of 121 pediatric medical journals (2012 Journal Citation Reports®, published by Thomson Reuters). URL: www.jpeds.com
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
+1 513 636 7140